ConductScience.org, home

Comparison · NCT01205776-774a5209

Percutaneous Coronary Intervention (PCI) vs Coronary Artery Bypass Graft (CABG): Number of Participants With All Revascularizations (Ischemia Driven and Not Ischemia Driven)

Calculated by ConductScience from the counts the trial posted to ClinicalTrials.gov.

2 sourcestrial-comparisons-2026-03-23-0.1.0

Download JSON
Cite this record

ConductScience Library. Percutaneous Coronary Intervention (PCI) vs Coronary Artery Bypass Graft (CABG): Number of Participants With All Revascularizations (Ischemia Driven and Not Ischemia Driven). Trial comparisons, record NCT01205776-774a5209. Release trial-comparisons-2026-03-23-0.1.0, 23 Mar 2026. https://conductscience.org/library/comparisons/NCT01205776-774a5209

On this page

Measures6

Calculated by ConductScience from the counts the trial posted to ClinicalTrials.gov.

MeasureValue95% interval, lower95% interval, upperMethodNote
Risk in group 10.1610.1390.186wilson
Risk in group 20.09610.0790.116wilson
Risk difference, group 1 minus group 20.06530.03530.0954newcombe hybrid score
Risk ratio, group 1 over group 21.681.322.14log
Odds ratio, group 1 over group 21.811.372.38log
Number needed to treat, for one more participant with the outcome on Percutaneous Coronary Intervention (PCI) than on Coronary Artery Bypass Graft (CABG)15.310.528.3from the risk difference interval

Groups2

Neither group, or both, names a comparator, so the groups keep ClinicalTrials.gov's order.

GroupTitleDescriptionWith the outcomeAnalysedClinicalTrials.gov code
Group 1Percutaneous Coronary Intervention (PCI)Those patients receiving the XIENCE PRIME™ EECSS or XIENCE V® EECSS or XIENCE Xpedition™ EECSS or XIENCE PRO EECSS153948OG000
Group 2Coronary Artery Bypass Graft (CABG)Those patients receiving Coronary Artery Bypass Graft (CABG)92957OG001

Outcome

Type
SECONDARY
Title
Number of Participants With All Revascularizations (Ischemia Driven and Not Ischemia Driven)
Description
* A target lesion (vessel) revascularization will be considered ischemia-driven if the target lesion diameter stenosis is ≥ 50% by QCA (analysis segment measurement, involving the lesion itself and 5 mm of proximal and/or distal margin) and any of the following criteria for ischemia are met:~ * A positive functional study corresponding to the area served by the target lesion;~ * Ischemic ECG changes at rest in a distribution consistent with the target vessel;~ * Typical ischemic symptoms referable to the target lesion;~ * IVUS of the target lesion with a minimal lumen area (MLA) of ≤ 4 mm\^2 for non left main lesions or ≤ 6 mm\^2 for left main lesions. If the lesions are de novo (i.e. not restenotic), the~ * plaque burden must also be ≥ 60%;~ * FFR of the target lesion ≤ 0.80~* A non target vessel revascularization will be considered ischemia-driven if any lesion the non target vessel has a diameter stenosis ≥ 50% by QCA with any of the above criteria for ischemia met.
Time frame
0 to 5 years
Population
ITT population.

Source ClinicalTrials.gov

Trial

Title
EXCEL Clinical Trial
NCT number
NCT01205776
Phases
NA
Conditions
Chronic Coronary Occlusion, Unprotected Left Main Coronary Artery Disease, Stent Thrombosis, Vascular Disease, Myocardial Ischemia, Coronary Artery Stenosis, Coronary Disease, Coronary Artery Disease, Coronary Restenosis
Interventions
Percutaneous Coronary Intervention, CABG
Lead sponsor
Abbott Medical Devices
Results first posted
2018-03-29

Source ClinicalTrials.gov

Source

Release
trial-comparisons-2026-03-23-0.1.0
Release manifest SHA-256
f66225897fbf258b57ea10bdacfd0347d3cdfda93f7f5685234b7e06ea36fa57
AACT copy
2026-03-23
Tables read
outcome_counts.parquet, outcome_measurements.parquet, outcomes.parquet, reported_event_totals.parquet, reported_events.parquet, result_groups.parquet, studies.parquet, ctgov_trial.parquet

Source ClinicalTrials.gov

Sources 2

  • ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
  • ClinicalTrials.govNo license stated
Each source's terms
  • ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
  • ClinicalTrials.govnone stated

ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions. The measures are ConductScience's calculation from them.

For software

Read this comparison from software.

The record is JSON. No key.

GET https://conductscience.org/api/comparisons/v1/NCT01205776-774a5209